Understanding the β-Lactam/Inhibitor of β-Lactamase Combinations: Reassessment for Better Antimicrobial Stewardship

Perez, Leandro Reus Rodrigues; Narváez, Gabriel

doi:10.1017/ice.2017.93

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbapenems are frequently used in the treatment of infections caused by these microorganisms [24] . An increase in the frequency of carbapenem-resistant gram-negative bacteria has been observed over the last decade due to widespread carbapenem use [25] . Recent emphasis on the rational use of antimicrobial agents has necessitated the investigation of alternatives to carbapenems for the treatment of infections with ESBLproducing microorganisms [26] .…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Ayhan¹,

Kayaaslan²,

Hasanoğlu³

et al. 2020

mjima

View full text Add to dashboard Cite

Infections with extended-spectrum beta-lactamase (ESBL)-producing strains are seen at increasing rates, resulting in increased morbidity, mortality, length of hospitalization, and cost. Effective and safe treatment of these infections is important. The aim of this study was to compare the effectiveness of piperacillin-tazobactam (PTZ) and carbapenems in nosocomial infections with ESBL-producing Escherichia coli and Klebsiella pneumoniae in hospitalized patients. Materials and Methods: This study was performed retrospectively on patients who were infected with ESBL-producing E. coli and K. pneumoniae while hospitalized in Ankara Atatürk Tranining and Research Hospital between 2014 and 2017. Both PTZ-and carbapenem-susceptible isolates were included in the study. Patients with signs of infection who were older than 18 years, hospitalized for at least 48 hours, and received PTZ or carbapenem therapy were included in the study. Patients who received PTZ and carbapenem antibiotics consecutively in same infectious episode, received another antibiotic active against ESBL-producing microorganisms, received the selected antibiotic for less than 48 hours, or had polymicrobial infection were excluded from the study. Demographic characteristics, comorbid diseases, antibiotics used and their dose/duration, mechanical ventilation, presence of central catheter, clinical and microbiological responses to treatment, and end-of-treatment and 30-day mortality were recorded and compared. Results: Of the total 113 patients, 60 (53.1%) were male and the mean age was 66.14±18.2 years. Of the patients, 73.5% had E. coli and 26.5% had K. pneumoniae. Seventy patients (61.9%) received carbapenem and 43 patients (38.1%) received PTZ treatment. Microbiological eradication rate was 71.7% (43/60) in patients with control cultures. Clinical response was observed in 72.6% of the cases. The overall mortality rate was 31.0% (n=35). There were no significant differences between the groups in clinical and microbiological response (p=0.055; p=0.303) or end-of-treatment and 30day mortality (p=0.180, p=0.288). Age and bacteremia was found to be independent risk factors for mortality (p=0.006 for both). Conclusion: PTZ is an important alternative for infections caused by ESBL-producing microorganisms. In recent years, the need for rational antibiotic use has increased and carbapenem-sparing treatments have became more important. Piperacillin-tazobactam is one of the best alternatives and has comparable effectiveness in infections caused by ESBL-producing E. coli and Klebsiella spp.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Ayhan¹,

Kayaaslan²,

Hasanoğlu³

et al. 2020

mjima

View full text Add to dashboard Cite

show abstract

“…ESBL-producing organisms were the most prevalent in this survey, and they are frequently resistant to multiple antimicrobial agents, which greatly limits therapeutic options. 3,6 Currently, carbapenems are recommended for the treatment of serious infections caused by ESBL-producing organisms. On the other hand, additional data on ESBL incidence and risk factors for infection and/or colonization are needed to better establish the use of carbapenems.…”

mentioning

confidence: 99%

Understanding the β-Lactam/Inhibitor of β-Lactamase Combinations: Reassessment for Better Antimicrobial Stewardship

Cited by 2 publications

References 11 publications

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Nosocomial impact of prevalent β-lactamases from the community enterobacteriaceae: what to do when the resistance doesn’t go your way

Contact Info

Product

Resources

About